Read Time:15 Second
Viking Therapeutics Inc.’s stock fell 5.6% Friday, in a pullback from recent highs, after strong data from Novo Nordisk on an oral version of its weight-loss drug raised the competitive bar for Viking, which is expected to release data from its oral-drug trial late this quarter.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
